- Home
- PETZ vs POAI Comparison
PETZ vs POAI Comparison
Compare PETZ & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- POAI
- Stock Information
- Founded
- PETZ 2002
- POAI 2002
- Country
- PETZ China
- POAI United States
- Employees
- PETZ N/A
- POAI N/A
- Industry
- PETZ Steel/Iron Ore
- POAI Industrial Specialties
- Sector
- PETZ Industrials
- POAI Health Care
- Exchange
- PETZ Nasdaq
- POAI Nasdaq
- Market Cap
- PETZ 10.3M
- POAI 8.9M
- IPO Year
- PETZ 2017
- POAI N/A
- Fundamental
- Price
- PETZ $0.95
- POAI $0.88
- Analyst Decision
- PETZ
- POAI Hold
- Analyst Count
- PETZ 0
- POAI 1
- Target Price
- PETZ N/A
- POAI N/A
- AVG Volume (30 Days)
- PETZ 11.7K
- POAI 230.8K
- Earning Date
- PETZ 04-28-2025
- POAI 05-15-2025
- Dividend Yield
- PETZ N/A
- POAI N/A
- EPS Growth
- PETZ N/A
- POAI N/A
- EPS
- PETZ 0.26
- POAI N/A
- Revenue
- PETZ $563,726.00
- POAI $1,729,269.00
- Revenue This Year
- PETZ N/A
- POAI $486.27
- Revenue Next Year
- PETZ N/A
- POAI $65.50
- P/E Ratio
- PETZ $4.65
- POAI N/A
- Revenue Growth
- PETZ 74664.72
- POAI 24.17
- 52 Week Low
- PETZ $0.65
- POAI $0.55
- 52 Week High
- PETZ $1.74
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- PETZ 47.17
- POAI 36.28
- Support Level
- PETZ $0.86
- POAI $0.87
- Resistance Level
- PETZ $0.96
- POAI $0.97
- Average True Range (ATR)
- PETZ 0.07
- POAI 0.08
- MACD
- PETZ 0.01
- POAI -0.02
- Stochastic Oscillator
- PETZ 75.39
- POAI 4.65
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.